Business Description
PURE Bioscience Inc
NAICS : 325620
SIC : 2843
ISIN : US74621T2096
Total Employee Number:
12Description
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, and products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The company generates revenue from the sale of its antimicrobial products.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | -3.75 | |||||
Debt-to-Equity | -1.11 | |||||
Debt-to-EBITDA | -3.58 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -129.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.6 | |||||
3-Year EBITDA Growth Rate | 19.9 | |||||
3-Year EPS without NRI Growth Rate | 20 | |||||
3-Year FCF Growth Rate | 13.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.9 | |||||
9-Day RSI | 59.91 | |||||
14-Day RSI | 56.95 | |||||
3-1 Month Momentum % | -2.31 | |||||
6-1 Month Momentum % | 40.19 | |||||
12-1 Month Momentum % | -5.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.42 | |||||
Quick Ratio | 0.36 | |||||
Cash Ratio | 0.27 | |||||
Days Inventory | 72.12 | |||||
Days Sales Outstanding | 49.55 | |||||
Days Payable | 289.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | -20.61 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.84 | |||||
Operating Margin % | -79.11 | |||||
Net Margin % | -91.04 | |||||
EBITDA Margin % | -74.86 | |||||
FCF Margin % | -73.49 | |||||
OCF Margin % | -73.49 | |||||
ROA % | -195.24 | |||||
ROIC % | -135.94 | |||||
3-Year ROIIC % | -180.3 | |||||
ROC (Joel Greenblatt) % | -18150 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.49 | |||||
EV-to-EBIT | -8.53 | |||||
EV-to-EBITDA | -8.54 | |||||
EV-to-Revenue | 6.4 | |||||
EV-to-FCF | -8.7 | |||||
Price-to-GF-Value | 0.77 | |||||
Price-to-Median-PS-Value | 0.43 | |||||
Earnings Yield (Greenblatt) % | -11.72 | |||||
FCF Yield % | -17.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PURE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PURE Bioscience Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.422 | ||
| EPS (TTM) ($) | -0.02 | ||
| Beta | 0.1203 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.36 | ||
| Volatility % | 83.25 | ||
| 14-Day RSI | 56.95 | ||
| 14-Day ATR ($) | 0.00951 | ||
| 20-Day SMA ($) | 0.064811 | ||
| 12-1 Month Momentum % | -5.82 | ||
| 52-Week Range ($) | 0.0386 - 0.14 | ||
| Shares Outstanding (Mil) | 130.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PURE Bioscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PURE Bioscience Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2026-12-15 | In 142 days | ||
| Annual report for 2026 | 2026-10-29 | In 95 days | ||
| Third quarter earnings results for 2026 | 2026-06-15 | 0.07 (+7.38%) | ||
| Second quarter earnings results for 2026 | 2026-03-17 | 0.08 (+6.52%) | ||
| General meeting for 2026 | 2026-02-17 10:30 | 0.05 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-12-15 | 0.05 (-2.44%) | ||
| Annual report for 2025 | 2025-10-29 | 0.08 (-3.03%) | ||
| Third quarter earnings results for 2025 | 2025-06-16 | 0.08 (-12.63%) | ||
| Second quarter earnings results for 2025 | 2025-03-17 | 0.07 (+42.74%) | ||
| General meeting for 2025 | 2025-01-22 10:30 | 0.07 (-1.19%) |
Show
Entries
PURE Bioscience Inc Frequently Asked Questions
What is PURE Bioscience Inc(PURE)'s stock price today?
The current price of PURE is $0.08. The 52 week high of PURE is $0.14 and 52 week low is $0.04.
When is next earnings date of PURE Bioscience Inc(PURE)?
The next earnings date of PURE Bioscience Inc(PURE) is 2026-09-15 Est..
Does PURE Bioscience Inc(PURE) pay dividends? If so, how much?
PURE Bioscience Inc(PURE) does not pay dividend.
Guru Commentaries on OTCPK:PURE
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| PURE Bioscience Reports Fiscal Third Quarter 2026 Financial Results | 2026-06-15 | ||
| Hydrite Named Exclusive Distributor for PURE Bioscience in Dairy and Plant-Based Protein Market | 2022-11-02 |
Articles on PURE Bioscience Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers